Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
62.95
+0.79 (+1.27%)
Streaming Delayed Price
Updated: 12:15 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Annual Changes To The Nasdaq-100 Index
December 11, 2021
The reconstituted Nasdaq index for 2022 (effective Dec. 20, 2021) has six new members; they replace FOX, TCOM, INCY, CDW, CERN, and CHKP.
Via
Talk Markets
7 CEOs That Ought to Follow Jack Dorsey Out the Door
December 10, 2021
Jack Dorsey stepped down as Twitter CEO despite stock gains, but not every CEO can say the same. Here are seven CEOs who need to go.
Via
InvestorPlace
7 Stocks 'On Sale' This Holiday Season
November 26, 2021
This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have...
Via
Talk Markets
7 Stocks 'On Sale' This Holiday Season
November 26, 2021
The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Expert Ratings For Incyte
November 19, 2021
Over the past 3 months, 6 analysts have published their opinion on Incyte (NASDAQ:
Via
Benzinga
Expert Ratings For Incyte
September 23, 2021
Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Stocks Most Impacted by 7-10 Year Treasuries
November 17, 2021
A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript
November 02, 2021
INCY earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus
November 02, 2021
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas
November 01, 2021
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),...
Via
Benzinga
Exposures
Product Safety
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
October 27, 2021
It's much too early to count these companies out.
Via
The Motley Fool
Could This Be the Next Blockbuster Indication for Eli Lilly?
October 21, 2021
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.
Via
The Motley Fool
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
September 27, 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...
Via
Benzinga
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
September 23, 2021
Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
September 23, 2021
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as...
Via
Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
10 Biggest Price Target Changes For Thursday
September 23, 2021
Deutsche Bank reduced the price target for FedEx Corporation (NYSE:
Via
Benzinga
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
September 22, 2021
The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for...
Via
Benzinga
Exposures
Product Safety
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
September 22, 2021
Find out what held these laggards back.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.